Novo Nordisk A/S and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared

SG&A Spending: Novo Nordisk vs. Supernus Pharmaceuticals

__timestampNovo Nordisk A/SSupernus Pharmaceuticals, Inc.
Wednesday, January 1, 20142676000000072471000
Thursday, January 1, 20153216900000089204000
Friday, January 1, 201632339000000106010000
Sunday, January 1, 201732124000000137905000
Monday, January 1, 201833313000000159888000
Tuesday, January 1, 201935830000000158425000
Wednesday, January 1, 202036886000000200677000
Friday, January 1, 202141058000000304759000
Saturday, January 1, 202250684000000377221000
Sunday, January 1, 202361598000000336361000
Monday, January 1, 202467377000000
Loading chart...

Igniting the spark of knowledge

SG&A Spending Patterns: A Tale of Two Companies

In the world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Novo Nordisk A/S, a global leader in diabetes care, and Supernus Pharmaceuticals, Inc., a specialist in central nervous system disorders, present a fascinating contrast in their SG&A spending from 2014 to 2023.

Novo Nordisk's SG&A expenses have surged by approximately 130% over the decade, reflecting its aggressive market expansion and robust R&D investments. In 2023, their SG&A spending reached a peak, highlighting their commitment to maintaining a competitive edge. Conversely, Supernus Pharmaceuticals, while smaller in scale, has shown a steady increase in SG&A expenses, growing by nearly 365% over the same period. This growth underscores their strategic focus on expanding their market presence and enhancing operational efficiency.

These spending patterns reveal the distinct strategies employed by each company to navigate the competitive pharmaceutical landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025